Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10124202" target="_blank" >RIV/00179906:_____/13:10124202 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10124202

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2012.04643.x/pdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2012.04643.x/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1468-3083.2012.04643.x" target="_blank" >10.1111/j.1468-3083.2012.04643.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers

Popis výsledku v původním jazyce

Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for chronic plaque psoriasis. However, its use is hampered by the risk of liver fibrosis. The study compared the results of serial measurements of serum fibrosis markers during the remission-induction phase of treatment with MTX to those of patients on biologic therapy and long-term MTX therapy (> 2 years). Serum concentrations of hyaluronic acid (HA), N-terminal propeptide of collagen type III (PIIINP) and the results of two multi-test algorithms Fibrotest and Hepascore were evaluated in patients with chronic plaque psoriasis (N=24, age: 28-79 years, baseline psoriasis area and severity index PASI 13.5, range 2.2-33) at baseline and weeks 16 and 26 after the start of pharmacokinetically-guided therapy with MTX (Group A). Patients on established therapy with biologics (N=15, Group B) and long-term MTX users (N=10, Group C) with the mean baseline PASI scores of 0.9 and 1.2 were studied in parallel cohorts. At bas

Název v anglickém jazyce

Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers

Popis výsledku anglicky

Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for chronic plaque psoriasis. However, its use is hampered by the risk of liver fibrosis. The study compared the results of serial measurements of serum fibrosis markers during the remission-induction phase of treatment with MTX to those of patients on biologic therapy and long-term MTX therapy (> 2 years). Serum concentrations of hyaluronic acid (HA), N-terminal propeptide of collagen type III (PIIINP) and the results of two multi-test algorithms Fibrotest and Hepascore were evaluated in patients with chronic plaque psoriasis (N=24, age: 28-79 years, baseline psoriasis area and severity index PASI 13.5, range 2.2-33) at baseline and weeks 16 and 26 after the start of pharmacokinetically-guided therapy with MTX (Group A). Patients on established therapy with biologics (N=15, Group B) and long-term MTX users (N=10, Group C) with the mean baseline PASI scores of 0.9 and 1.2 were studied in parallel cohorts. At bas

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS10364" target="_blank" >NS10364: Pilotní studie neinvazivního monitorování hepatotoxicity v průběhu dlouhodobé farmakokineticky řízené léčby psoriázy metotrexátem a kyselinou listovou</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1007-1014

Kód UT WoS článku

000321893600011

EID výsledku v databázi Scopus

—